Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 5.7% - Time to Sell?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) fell 5.7% during mid-day trading on Monday . The stock traded as low as $26.41 and last traded at $26.41. 52,164 shares traded hands during trading, a decline of 73% from the average session volume of 192,814 shares. The stock had previously closed at $28.00.

Analyst Ratings Changes

DNTH has been the subject of a number of recent research reports. Robert W. Baird initiated coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They issued an "outperform" rating and a $58.00 target price for the company. Lifesci Capital upgraded Dianthus Therapeutics to a "strong-buy" rating in a report on Tuesday, June 11th. Cantor Fitzgerald assumed coverage on Dianthus Therapeutics in a report on Thursday, June 27th. They set an "overweight" rating on the stock. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Thursday, September 26th. Finally, Wedbush cut their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating on the stock in a research note on Friday, August 9th. Nine analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $45.13.

Dianthus Therapeutics Stock Down 5.4 %

The business has a 50-day moving average price of $27.87 and a 200-day moving average price of $26.23. The firm has a market capitalization of $777.16 million, a price-to-earnings ratio of -4.44 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The firm had revenue of $1.86 million during the quarter, compared to analyst estimates of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. On average, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.32 earnings per share for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company's stock valued at $16,135,000 after acquiring an additional 384,182 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Dianthus Therapeutics by 860.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company's stock worth $2,095,000 after purchasing an additional 72,509 shares during the last quarter. Octagon Capital Advisors LP boosted its holdings in shares of Dianthus Therapeutics by 15.4% during the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company's stock worth $5,762,000 after purchasing an additional 74,000 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company's stock worth $788,000 after purchasing an additional 8,473 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Dianthus Therapeutics by 281.9% during the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company's stock worth $1,022,000 after purchasing an additional 29,159 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.